Cologuard company expects $1.7 billion revenues in 2021: 14 Takeaways from Exact Sciences quarterly earnings call
Last week, Exact Sciences announced its Q1 2021 results. Here are 14 takeaways from the earnings call.
The company outlined three priorities for 2021:
◘ Get more people tested
◘ Enhance customer experience
◘ Advancing new solutions
Let’s start with some numbers:
◘ Total revenue was $402.1 million, an increase of 16% (compare that to $347.8 million in Q1 2020 and $466.3 million in Q4 2020)
◘ Screening revenue was $240.3 million, an increase of 10% (compare that to $219.5 million in Q1 2019 and $249.7 million in Q4 2020)
◘ Precision Oncology revenue was $129.4 million (compare that to $117.6 million in Q4 2020)
◘ COVID-19 testing revenue was $32.3 million (compare that to $99.1 million in Q4 2020 and $102.2 million in Q3 2020)
Kevin Conroy, Chairman and CEO, Exact Sciences and Jeff Elliott, Chief Financial and Chief Operating Officer, Exact Sciences made these remarks.